VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: Yahoo! Finance
This compares to loss of $1.74 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this company would post a loss of $0.50 per share when it actually produced a loss of $0.20, delivering a surprise of 60%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. VYNE Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.1 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2%. This compares to year-ago revenues of $0.1 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. VYNE Therapeutics shares have added about 16.7
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- VYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- VYNE Therapeutics receives FDA approval for trial of VYN202 [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
- VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor [Yahoo! Finance]Yahoo! Finance
VYNE
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/3/24 - Form 4
- VYNE's page on the SEC website